51 patents currently held
384 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Of the 384 now held by other companies, 290 are held via Novartis AG, and 94 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Dec 2026
Next term end
35
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2033 · High confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends May 2032 · High confidence
Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists
US 9,744,234
Cited by 26 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies
US 11,801,300
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.
Methods of Treating Psoriasis Using IL-17 Antibody
US 9,717,791
Cited by 28 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Jan 2035 · High confidence
Cited by 172 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
held via Novartis AG
Also notable
Ends Oct 2032 · High confidence
Cited by 116 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Stamford Devices Ltd.
Also notable
Ends Feb 2032 · High confidence
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
US 8,637,508
Cited by 82 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
held via Novartis AG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 30, 2027The maintenance fee for Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies (US 11,801,300) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Selection Vectors and Methods of Selecting Eukaryotic Host Cells (US 11,807,855) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 3 fees due Jun 10 to 29, 2027 · next Jun 10
- 1 fee due Jul 9, 2027The maintenance fee for Formulations of (S)-3-Amino-6-Methoxy-N-(3,3,3-Trifluoro-2-Hydroxy-2-Methylpropyl)-5-(TRIFLUOROMETHYL)PICOLINAMIDE (US 11,865,109) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 2 fees due Sep 10 to 29, 2027 · next Sep 10
Recent changes
- Oct 14Assignment recorded on 1 record: Novartis Pharma AG to Novartis AG Recorded Oct 14, 2026, executed May 7, 2015. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76662, frame 75.
- 7 of the patents on this record were granted since Aug 18, 2026
- 6 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 35 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies | 7 in force | to Jan 2036 |
| Methods of Treating Psoriasis Using IL-17 Antibody | 6 in force | to May 2032 |
| Compositions and Methods for Use for Antibodies Against Sclerostin | 3 in force | to Oct 2028 |
| Antibodies to IL-15 | 2 in force | to Aug 2035 |
| Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists | 2 in force | to May 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,713,976 | Organic Compounds held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 7,713,977 | Organic Compounds held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 8,163,904 | Salts of 4-Methyl-N-[3-(4-Methyl-IMIDAZOL-1-YL)-5-Trifluoromethyl-PHENYL]-3-(4-Pyridin-3-YL-PYRIMIDIN-2-Ylamino)-BENZAMIDE held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 8,450,272 | Combinations of Somatostatin-Analogs with Different Selectivity for Human Somatostatin Receptor Subtypes held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 7,879,322 | Compositions and Methods for Use for Antibodies Against Sclerostin In force · High confidence | In force | High confidence | |
| US 8,246,953 | Compositions and Methods for Use for Antibodies Against Sclerostin In force · Medium confidence | In force | Medium confidence | |
| US 8,486,661 | Polynucleotides Encoding Antibodies Against Sclerostin and Uses Therefor In force · Medium confidence | In force | Medium confidence | |
| US 8,343,984 | Crystalline Forms of 4-Methyl-N- [3-(4-Methyl-IMIDAZOL-1-YL)-5-Trifluoromethyl-PHENYL]-3- (4-Pyridin-3-YL-PYRIMIDIN-2-Ylamino) -Benzamide held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 7,807,155 | IL-17 Antagonistic Antibodies In force · Low confidence | In force | Low confidence | |
| US 8,120,592 | Touch Sensing Substrate and Touch Sensing Liquid Crystal Display In force · High confidence | In force | High confidence |
Also on record, not counted in the 51: 384 patents in force now held by others · 286 patents ended · 204 applications pending · 540 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.